サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420415

帯状疱疹ワクチンの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品タイプ別、予防接種タイプ別、地域別

Shingles Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 250 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
帯状疱疹ワクチンの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品タイプ別、予防接種タイプ別、地域別
出版日: 2024年01月23日
発行: Fairfield Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の帯状疱疹ワクチンの市場規模は著しい成長を遂げており、2024年には約46億米ドルになるとみられています。同市場は今後10年間で驚異的な16%というCAGRを達成し、2031年末には130億米ドルに達する見込みです。

米国国立生物工学情報センターは、帯状疱疹の蔓延を防ぐ上で、帯状疱疹ワクチンが極めて重要な役割を果たすことを強調しています。特に免疫不全患者に対しては、帯状疱疹後神経痛（PHN）に対して既存の抗ウイルス治療が完全には有効ではないため、ワクチン開発の緊急性が高まっています。

特に60歳以上の高齢者は、免疫力の低下により帯状疱疹にかかりやすくなっています。米国疾病予防管理センター（CDC）の報告によると、全世界の帯状疱疹患者の半数はこの年齢層で発生しており、安全で費用対効果の高い帯状疱疹ワクチンの必要性が強調されています。帯状疱疹は致命的ではないもの、肺炎や脳炎などの健康合併症を引き起こす可能性があり、この層にとってワクチンは極めて重要です。

帯状疱疹の有病率は、地域や気候条件によって異なります。水痘帯状疱疹ウイルスによって引き起こされる帯状疱疹は、熱帯および亜熱帯地域で一般的です。低開発国、特に熱帯アジアでは、定期的な水痘ワクチン接種が行われていないため、帯状疱疹ワクチン市場にとって好機となっています。帯状疱疹ワクチン接種プログラムをWHOの予防接種地域戦略計画に組み込むことで、低開発地域の疾病負担と関連合併症を大幅に減らすことができます。

当レポートでは、世界の帯状疱疹ワクチン市場について調査し、市場の概要とともに、製品タイプ別、予防接種タイプ別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の帯状疱疹ワクチン市場の見通し、2018年～2031年

  • 世界の帯状疱疹ワクチン市場の見通し、製品タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界の帯状疱疹ワクチン市場の見通し、予防接種タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界の帯状疱疹ワクチン市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の帯状疱疹ワクチン市場の見通し、2018年～2031年

第5章 欧州の帯状疱疹ワクチン市場の見通し、2018年～2031年

第6章 アジア太平洋の帯状疱疹ワクチン市場の見通し、2018年～2031年

第7章 ラテンアメリカの帯状疱疹ワクチン市場の見通し、2018年～2031年

第8章 中東・アフリカの帯状疱疹ワクチン市場の見通し、2018年～2031年

第9章 競合情勢

  • 製品別と予防接種タイプ別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • SK Chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
    • Cipla Inc.
    • Pfizer Inc

第10章 付録

目次

The global Shingles Vaccine market is experiencing significant growth, with a valuation of approximately US$ 4.6 billion in 2024. According to the latest report by Fairfield Market Research, the market is poised to achieve a staggering CAGR of 16% over the next decade, reaching an estimated US$ 13 billion by the end of 2031.

Sales Analysis and Market Outlook

Fairfield Market Research reveals that the Shingles vaccine segment exhibited the highest revenue share during the forecasted period. The recombinant vaccine, within the vaccine type segment, dominated with an impressive growth rate CAGR over the forecasted period.

The National Center for Biotechnology Information emphasizes the pivotal role of Shingles vaccines in preventing the prevalence of herpes zoster, with an estimated 278 million cases expected globally in the coming decade in the absence of effective vaccination. The urgency for vaccine development is heightened, especially for immunocompromised patients, as existing antiviral treatments are not entirely effective for postherpetic neuralgia (PHN).

Shingles among Older Adults Driving Market Demand

Older adults, particularly those aged 60 and above, face an increased susceptibility to shingles due to weakened immune systems. The Centers for Disease Control and Prevention (CDC) reports that half of all shingles cases worldwide occur in this age group, emphasizing the need for a safe and cost-effective herpes zoster vaccine. Shingles, while not deadly, can lead to health complications such as pneumonia and encephalitis, making a vaccine crucial for this demographic.

Shingles Market Dynamics in Underdeveloped Countries

The prevalence of shingles varies based on geographical regions and prevailing climatic conditions. Shingles caused by the Varicella Zoster virus is common in tropical and subtropical regions. Underdeveloped countries, particularly in tropical Asia, lack routine varicella vaccination, presenting an opportunity for the shingles vaccine market. Integrating shingles vaccination programs into the WHO Regional Strategic Plan for Immunization in underdeveloped regions could significantly reduce disease burdens and associated complications.

Challenges and Impact of COVID-19 on Shingles Vaccine Market

Despite the positive outlook, challenges persist in developing effective shingles vaccines. The vaccine is typically administered before exposure to the Varicella Zoster virus, requiring strategic planning for efficacy. The latent reactivation of the virus in individuals with pre-existing immunity poses a challenge, necessitating the development of therapeutic vaccines for prompt immune response.

The COVID-19 pandemic had mixed effects on the Shingles vaccine market. Supply tensions and export bans initially disrupted vaccine rollouts, affecting sales. GlaxoSmithKline reported a significant drop in sales in the first quarter of 2021, attributed to disruptions caused by COVID-19 vaccine rollouts. However, the market rebounded in 2022, with GlaxoSmithKline's Shingles vaccine witnessing high revenue, reflecting a strong demand that outpaced supply after the pandemic.

Regional Growth and Market Analysis

Europe is emerging as a key growth region for the Shingles vaccine market, with the U.K. leading the way. The U.K. approved the shingles vaccine in its immunization program, achieving a vaccination rate of approximately 60%. Initiatives by key vaccine companies, such as GlaxoSmithKline plc., are contributing to the market's momentum. The expected growth rate in the European shingles market is estimated at 17% from 2024 to 2031, with an absolute dollar opportunity growth by 2032.

Country-Specific Insights

South Korea: The shingles vaccine market in South Korea is valued significantly in 2031. Revenue from shingles vaccines witnessed a substantial growth rate over the period from 2018 to 2023. Korean companies are actively expanding their presence in the global market with their shingles vaccines. Despite entering the shingles vaccine market relatively late, South Korea has achieved remarkable success, becoming the world's second-largest vaccine producer. SK Bioscience introduced Sky Zoster as a global solution for treating herpes zoster. SK Bioscience has also initiated efforts for the approval of 'Sky Zoster' in South Asian countries and is actively engaged in global clinical trials and expanding its product reach in the United States, China, and Europe. South Korea is expected to experience significant absolute dollar opportunity growth in the shingles vaccine market between 2024 and 2031.

China: China plays a prominent role in the shingles vaccine market, following the United States. The market in China holds substantial value in 2031 and is projected to witness substantial absolute dollar opportunity growth during the forecasted period. China achieved a notable growth rate in the shingles vaccine market from 2018 to 2023.

Competitive Analysis:

The competitive landscape showcases strategic developments by key players, positioning them for continued success in the dynamic vaccine market.

Key Companies Profiled

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • SK Chemicals
  • Green Cross Corp
  • Geneone Life Science
  • Vaccitech
  • CanSinoBIO
  • Cipla Inc.
  • Pfizer Inc

Diverse Segments Explored in Comprehensive Shingles Vaccine Industry Study

Shingles Vaccine Market by Product Type:

  • Shingles
  • Zostavax
  • Sky Zoster

Shingles Vaccine Market by Vaccine Type:

  • Recombinant Vaccine
  • Live Attenuated Vaccine

Shingles Vaccine Market by Region:

  • North America Shingles Vaccine Market
  • Latin America Shingles Vaccine Market
  • Europe Shingles Vaccine Market
  • South Asia Shingles Vaccine Market
  • East Asia Shingles Vaccine Market
  • Oceania Shingles Vaccine Market
  • Middle East & Africa Shingles Vaccine Market

Table of Contents

1. Executive Summary

  • 1.1. Global Shingles Vaccine Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Shingles Vaccine Market Outlook, 2018 - 2031

  • 3.1. Global Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Shingles
      • 3.1.1.2. Zostavax
      • 3.1.1.3. Sky Zoster
  • 3.2. Global Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Recombinant Vaccine
      • 3.2.1.2. Live Attenuated Vaccine
  • 3.3. Global Shingles Vaccine Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Shingles Vaccine Market Outlook, 2018 - 2031

  • 4.1. North America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Shingles
      • 4.1.1.2. Zostavax
      • 4.1.1.3. Sky Zoster
  • 4.2. North America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Recombinant Vaccine
      • 4.2.1.2. Live Attenuated Vaccine
  • 4.3. North America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Shingles Vaccine Market Outlook, 2018 - 2031

  • 5.1. Europe Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Shingles
      • 5.1.1.2. Zostavax
      • 5.1.1.3. Sky Zoster
  • 5.2. Europe Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Recombinant Vaccine
      • 5.2.1.2. Live Attenuated Vaccine
  • 5.3. Europe Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Shingles Vaccine Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Shingles
      • 6.1.1.2. Zostavax
      • 6.1.1.3. Sky Zoster
  • 6.2. Asia Pacific Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Recombinant Vaccine
      • 6.2.1.2. Live Attenuated Vaccine
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Shingles Vaccine Market Outlook, 2018 - 2031

  • 7.1. Latin America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Shingles
      • 7.1.1.2. Zostavax
      • 7.1.1.3. Sky Zoster
  • 7.2. Latin America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Recombinant Vaccine
      • 7.2.1.2. Live Attenuated Vaccine
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Shingles Vaccine Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Shingles
      • 8.1.1.2. Zostavax
      • 8.1.1.3. Sky Zoster
  • 8.2. Middle East & Africa Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Recombinant Vaccine
      • 8.2.1.2. Live Attenuated Vaccine
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Vaccination Type Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GlaxoSmithKline plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Merck & Co., Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. SK Chemicals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Green Cross Corp
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Geneone Life Science
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Vaccitech
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. CanSinoBIO
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Cipla Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Pfizer Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations